tbuckley/cabot-search huggingface dataset:
Correction
Journal: BMJ (1983)

Report urges better NHS auditAn official report making several recom- mendations for improving audit of how the National Health Service uses its resources was published on 11 August.The report, prepared by a combined Department of Health and Social Services and NHS working party chaired by Mr Patrick Salmon, proposes that all health authorities should produce audit plans that aim to achieve a minimum acceptable level of audit in all key areas of financial responsibility.Suggesting that authorities, especially smaller ones, should join together in consortiums to provide audit cover, the report says that until they gain sufficient skills in computer audit the DHSS should provide specialist support.Other proposals for strengthening audit procedures are also put forward for consideration.In his introduction to the report Mr Salmon says that the working party believed that "the management of the funds is just as critical as the uses to which the funds, are put," and that it was crucial for there to be "a central point within the Department to determine the problems
Medullary Thyroid Carcinoma Cell Lines Contain a Self-Renewing CD133+ Population that Is Dependent on RET Activity
Authors: Wen Zhu, Tao Hai, Lei Ye, Gilbert J. Cote
Journal: Endocrine Reviews (2009)

Medullary thyroid carcinoma (MTC) is a cancer of the parafollicular C cells commonly caused by an inherited or acquired RET protooncogene mutation. Therapeutic resistance and recurrence of the disease imply the presence of cancer stem cells in MTC. In this study, we sought to identify and characterize cancer stem cell-like cells in MTC. The characterization of stem cell properties was performed using immunostaining, flow cytometry, sphere formation assay, rederivation assay, Western blotting, and quantitative RT-PCR of defined markers of neural stem and progenitor cells. The role of RET activation was assessed through RNA interference knockdown. CD133 positivity was identified by immunostaining patient MTC. Flow cytometry confirmed a subpopulation of CD133+ cells in two MTC cell lines. The CD133+ cells could be expanded by sphere formation assay, passaged multiple times, and expressed neural progenitor markers β-tubulin 3 and glial fibrillary acidic protein. The MZ-CRC-1 cell line, which harbors a M918T RET mutation, had greater CD133+ cell numbers and sphere-forming ability than the TT cell line, which harbors the less active C634W mutation. Sphere formation was more dependent on RET activity than epidermal growth factor or fibroblast growth factor. Our data support the existence of cancer stem-like cells in MTC, which exhibit the features of self-renewal and of multiple lineage differentiation that is dependent on RET receptor activity. These findings may provide new insights to develop more promising therapy for MTC.
Medical News
Journal: JAMA (1975)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pamphlets Received.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
High rate of TTV infection in multitransfused patients with pediatric malignancy and hematological disorders
Authors: Miho Maeda, Hisamitsu Hamada, Akio Tsuda, Kiyoshi Kaneko, Yoshitaka Fukunaga
Journal: American Journal of Hematology (2000)

The prevalence of transfusion-transmitted virus (TTV) infection has not been known in patients suffering from pediatric malignancies and hematological disorders who receive blood transfusion and/or blood products during treatment.Blood samples were taken from 75 patients.TTV infection was identified when TTV DNA was detected in serum by a polymerase chain reaction (PCR) assay.Hepatitis C virus (HCV) and hepatitis G virus (HGV) RNA were also assayed by PCR.TTV DNA was detected in 38 of 75 patients (51%).In 4 of 38 patients, the amount of blood transfused was less than 3 units.By time since last transfusion, TTV DNA was detected in 12 of 35 patients after more than 4 years, 12 of 21 between 1 and 4 years, and 14 of 19 within 1 year.Six patients had mixed infection of TTV and HCV, and 12 patients had mixed infection of TTV and HGV.Three different kinds of virus were found simultaneously in serum from 3 patients.Eight out of 75 patients showed abnormal levels of alanine aminotransferase (ALT) (>40 IU/liter), and 3 of them had TTV DNA.All patients who had TTV DNA and elevated ALT levels also were positive for HCV RNA and HGV RNA.The prevalence of TTV infection is high in patients with pediatric malignancies and hematological disorders after episodes of blood transfusion.Transfusion is one of the most important risk factors for TTV infection regardless of the amount of blood transfused.Am.
CHILD LABOR REFORM.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
Authors: D.S.W. Tan, U.N. Lassen, C.M. Albert, S. Kummar, C. van Tilburg, S.G. Dubois, B. Geoerger, L. Mascarenhas, N. Federman, A. Basu-Mallick, F. Doz, J.D. Berlin, D.-Y. Oh, S. Bielack, R. McDermott, S. Cruickshank, N.C. Ku, M.C. Cox, A. Drilon, D.S. Hong
Journal: Annals of Oncology (2018)
PTU-177 Retrospective Audit of Management of Patients Admitted to Intensive Care unit (ITU) with Severe Acute Pancreatitis(SAP): Abstract PTU-177 Table
Authors: O Jalil, A Iqbal, C Patel, R Radwan, A Rasheed
Journal: Gut (2013)

<h3>Introduction</h3> To compare management strategies and mortality of patients admitted to ITU with SAP against national standards and study the group who succumbed to their disease in detail to identify the most accurate prognostic indicators in this group of patients. <h3>Methods</h3> Retrospective audit of management and outcome of consecutive patients admitted to ITU with SAP during 2007–2010. The development of necrosis and organ failure(OF)was recorded. Patients were classified into four groups: I (No necrosis or OF), II (sterile necrosis or transient OF), III (infected necrosis or persistent OF) and IV (infected necrosis and persistent OF). <h3>Results</h3> Fifty one patients were admitted to ITU with SAP (APACHE II &gt; 8, modified Glasgow score &gt; 3). All cases fulfilled the Atlanta criteria of SAP. Median age: 66 ± 17.5. The overall mortality rate was 38% (n-19) above national standard of 30%. All 7 patients in group IV died, 5 of them underwent necrosectomy and 1 had CT guided drainage of infected acute fluid collection. The table shows the total number of patients and respective mortality in each group. Neither antibiotics nor nutritional support had significant impact on survival. Outcome (death) correlated with organ dysfunction criteria (Atlanta criteria and APACHE II score). <h3>Conclusion</h3> While the presence of infected necrosis or persistent organ failure in SAP (group III) is associated with high mortality, the combination of “infected necrosis and persistent organ failure” (group IV) is uniformly fatal. Further research is necessary to confirm our findings and to explore ways of optimising patients in group III to improve survival. <h3>Disclosure of Interest</h3> None Declared.
Correction: Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups
Authors: A Burns, R Alsolami, J Becq, B Stamatopoulos, A Timbs, D Bruce, P Robbe, D Vavoulis, R Clifford, M Cabes, H Dreau, J Taylor, S J L Knight, R Mansson, D Bentley, R Beekman, J I Martín-Subero, E Campo, R S Houlston, K E Ridout, A Schuh
Journal: Leukemia (2019)

An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Is methotrexate an effective and safe treatment for maintaining hair regrowth in people with alopecia totalis? A critically appraised topic
Authors: R. Browne, L. Stewart, H.C. Williams
Journal: British Journal of Dermatology (2018)

Alopecia areata (AA) is a common disorder causing hair loss, which can range from patches, to complete hair loss on the scalp (alopecia totalis), or involving all hair‐bearing sites (alopecia universalis). It can cause anxiety, depression and low self‐esteem. Treatment can be difficult – there are several options but they don't always work and can have unwanted side effects. Hair can in fact regrow without any treatment. The aim of this study was to assess the current evidence regarding use of a drug called methotrexate for getting hair to regrow, and then remain, in people with alopecia. The authors looked at 13 studies comprising 226 patients with alopecia varying from 30% hair loss to alopecia universalis at the start. Methotrexate was usually given with drugs called systemic corticosteroids to start hair regrowth rather than regrowth maintenance. Regrowth, defined as anything from 50% to complete regrowth, was reported in 20‐90% of patients. Relapse (meaning hair re‐grew but then fell out again) occurred in 20‐80%, with variable regrowth on retreatment. Unwanted side effects ranged from 7‐60%. The authors found insufficient evidence to conclude whether methotrexate is useful for maintaining regrowth in extensive alopecia areata. They found some evidence to suggest that hair regrowth may be started by methotrexate when used in combination with systemic corticosteroids, but it was difficult to say which of the treatments this was due to, or if the hair was going to regrow anyway. Further trials are needed.
Nephrolithiasis
Authors: Hibbard E. Williams
Journal: New England Journal of Medicine (1974)

FEW medical disorders can command the respect for age so clearly attributed to renal-stone disease. Nearly every tome on medical history recounts the well known antiquity of this malady. Nevertheless, the etiology, pathogenesis and successful therapy of stone disease remain poorly understood and inaccurately devised. The last five years have seen a rebirth of interest in renal-stone disease, with two international symposia being devoted to ongoing studies in the field. With such interest it is likely that the future will solve the many enigmas that have gone unanswered for so many centuries.Stone disease achieves notoriety not only by virtue . . .
Gastrointestinal Bleeding
Authors: T. A. Marek
Journal: Endoscopy (2005)

The number of abstracts concerning gastrointestinal bleeding presented at the Digestive Disease Week (DDW) meeting in 2005 was quite high, making the task of selecting abstracts for detailed review little difficult. Priority has been given to large meta-analyses and epidemiological studies, randomized controlled trials involving larger numbers of patients, descriptions of newer techniques, and abstracts presenting data significantly differing from what is commonly known. Abstracts on capsule endoscopy, in which obscure gastrointestinal bleeding is the most common indication, are the topic of a separate paper.
Complete Deficiency of Glycophorin A in Red Blood Cells From Mice With Targeted Inactivation of the Band 3 (AE1) Gene
Authors: Hani Hassoun, Toshihiko Hanada, Mohini Lutchman, Kenneth E. Sahr, Jiri Palek, Manjit Hanspal, Athar H. Chishti
Journal: Blood (1998)
A new mechanism of BRAF activation in human thyroid papillary carcinomas
Authors: Alfredo Fusco, Giuseppe Viglietto, Massimo Santoro
Journal: Journal of Clinical Investigation (2005)

In this issue of the JCI, Ciampi et al. report the identification of a novel oncogene in patients affected by radiation-associated thyroid papillary carcinomas. This oncogene derives from a paracentric inversion of the long arm of chromosome 7, which results in an in-frame fusion of the N-terminus of the A-kinase anchor protein 9 (AKAP9) gene with the C-terminal catalytic domain (exons 9–18) of the serine-threonine kinase BRAF. The resulting AKAP9-BRAF fusion protein shows constitutive kinase activity, and it is able to transmit mitogenic signals to the MAPK pathways and to promote malignant transformation of NIH3T3 cells.
Electroenceph &amp;amp; Clin Neurophysiol, Amsterdam
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 4802: <i>In vitro</i> characterization of TP-2846: a novel tetracycline antileukemia agent
Authors: Corey Fyfe, Joseph Newman, Ajay Bhargava, Juan Ballesteros, Alicia Robles, Cuixiang Sun, Xiao-Yi Xiao, Jacques Dumas
Journal: Cancer Research (2019)

Abstract Recently published studies suggest two hypotheses for the mechanism of action (MOA) of tetracyclines’ anticancer activities: a) disruption of mitochondrial translation (Škrtić, Cancer Cell (2011) 20(5): 10.015); b) regulation of the miRNA-199b-5p-HES1-AKT pathway (Yang, Mol Cancer Ther (2016) 15(3): 1535-7163.MCT-15-0709). Upon treatment with TP-2846, suppressed levels of cytochrome oxidase-1 (COX-1) levels were demonstrated in Western blots. The COX-1 mRNA accumulated approximately 1,000-fold over background levels after 48 h incubation. Furthermore, TP-2846 displayed sub-µM inhibitory activities to mitochondrial translation (IC50 = 0.71 µM) and ribosomal translation both in E. coli and in eukaryotes (IC50 = 0.56 µM and 3.75 µM, respectively). In addition, TP-2846 led to accumulation of the micro RNA miR-199b in MV4-11 and HL-60 cells after 24 h incubation. TP-2846 had minimal IC50 shift (Resistance Factor (RF) = 1.53) against K-562/ADR, a leukemia cell line overexpressing P-glycoprotein (Pgp), while daunorubicin displayed an RF value of 3.67 in the same assay. TP-2846 was also studied ex vivo using bone marrow samples from 15 AML patients, including those resistant to AraC, and displayed potent activity in all samples (EC50 = 150-250 nM), while anthracyclines had similar activity (EC50 = 100-600 nM) and AraC was 10x less potent (EC50 = 2.3 µM) in the same ex vivo assay. In summary, TP-2846 exhibits both anticancer MOAs described in the literature for tetracyclines, retains antiproliferation activity in resistant leukemia cell lines, and demonstrates promising ex vivo activity in bone marrow samples from AML patients. This data indicates that further investigations in vitro and in vivo are warranted (see accompanying abstract “In vivo activities of TP-2846: a novel tetracycline antileukemia agent”). Citation Format: Corey Fyfe, Joseph Newman, Ajay Bhargava, Juan Ballesteros, Alicia Robles, Cuixiang Sun, Xiao-Yi Xiao, Jacques Dumas. In vitro characterization of TP-2846: a novel tetracycline antileukemia agent [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4802.
BRAZIL
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Journal Amer Geriatrics Society, Baltimore
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment
Authors: Ash A. Alizadeh, Andrew J. Gentles, Alvaro J. Alencar, Holbrook E Kohrt, Roch Houot, Matthew J Goldstein, Shuchun Zhao, Yasodha Natkunam, Ranjana Advani, Randy D. Gascoyne, Javier Briones, Robert J. Tibshirani, June Helen Myklebust, Sylvia K. Plevritis, Izidore S Lossos, Ronald Levy
Journal: Blood (2010)
Error in Author Affiliations
Authors: João Ferreira, Nicolas Girerd, Faiez Zannad
Journal: JAMA Cardiology (2018)

Iona Y. Millwood, DPhil; Derrick A. Bennett, PhD; Michael V. Holmes, PhD; Ruth Boxall, MSc; Yu Guo, MSc; Zheng Bian, MSc; Ling Yang, PhD; Sam Sansome, BSc; Yiping Chen, DPhil; Huaidong Du, PhD; Canqing Yu, PhD; Alex Hacker, MA; Dermot F. Reilly, PhD; Yunlong Tan, MBBS; Michael R. Hill, PhD; Junshi Chen, MD; Richard Peto, FRS; Hongbing Shen, PhD; Rory Collins, FRS; Robert Clarke, MD; Liming Li, MPH; Robin G. Walters, PhD; Zhengming Chen, DPhil; for the China Kadoorie Biobank Collaborative Group
New England Journal of Medicine, Boston
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal